Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Mole101on May 18, 2021 12:11am
157 Views
Post# 33220137

RE:RE:For newbies wanting to learn about PMN310

RE:RE:For newbies wanting to learn about PMN310

Chages are happening FarmerJ, have a look at last few weeks NRs. We are getting new faces on the board and I'm looking forward to see Who the new CEO is going to be. I'm confident the Antobody test will move forward too. There is plenty of time to use it ahead of us , this pandemic isn't going away anytime soon..
 

https://www.google.ca/amp/s/amp.theguardian.com/world/2021/may/17/uk-cases-of-indian-covid-variant-almost-doubled-in-four-days-says-hancock


farmerjane wrote: I don't think any newbies, will need real news for that to happen?

This video is a couple of years old, doesn't bode well for taking 310 into the clinic, just more hot air!! Patience qucikly running out for many investors who are not getting any information. The Covid test seemed possible a few weeks ago but less and less likely new excuses, delays!!

The Prelimanary Short Term Prospectus dated November 26, 2019. Business Objectives and Milestones from that Placing. Scienticfic validation of preclinical therapeutic programs, Timing Q1 2021. Validation and qualification of assays with patient serum samples. Q1, 21021. Create a pilot multivalent vaccine for assessment; identify improvements for potential subsequent development and evaluation, Q2, 2021. 

What have seen in news releases? Nlothing but old science where they say they need to further validate. The pattern of missing Business Objectives and Milestones have continued to miss,  timelines for quite a few years. Patience really running thin, things are going to hit the fan quickly!!



 

<< Previous
Bullboard Posts
Next >>